Table I.
Logistic regression analysis.
| All patients: anti‐S Ab positivity | Seropositive patients only: neutralising activity | |||||
|---|---|---|---|---|---|---|
| Seropositive, n/N | OR (95% CI) | P | Neutralising, n/N | OR (95% CI) | P | |
| Lymphocyte subsets | ||||||
| CD19 (1 log increase) | 23/54 | 1·32 (1·06–1·66) | 0·013 | 12/17 | 2·04 (0·99–4·22) | 0·054 |
| CD4 (1 log increase) | 23/53 | 2·50 (1·12–5·55) | 0·025 | 12/19 | 1·23 (0·28–5·39) | 0·78 |
| CD56 (1 log increase) | 23/53 | 4·47 (1·46–13·06) | 0·008 | 12/19 | 6·79 (0·62–73·92) | 0·12 |
| Treatments | ||||||
| Rituximab | ||||||
| No | 1/4 | 1·00 | 0·49 | 0/1 | — | 0·37* |
| Yes | 22/51 | 2·28 (0·22–23·39) | 12/18 | — | ||
| BTKi | ||||||
| No | 17/42 | 1·00 | 0·72 | 11/16 | 1·00 | 0·54 |
| Yes | 6/13 | 1·26 (0·36–4·41) | 2/4 | 0·57 (0·05–4·67) | ||
| CAR‐T | ||||||
| No | 221/46 | 1·00 | 0·21 | 13/18 | — | 0·37* |
| Yes | 2/9 | 0·34 (0·06–1·82) | 0/1 | — | ||
| Vaccine time‐point | ||||||
| On treatment | 9/25 | 1·00 | 0·026 | 3/7 | — | 0·034* |
| Within 6 months of treatment | 5/18 | 0·68 (0·18–2·55) | 2/5 | — | ||
| >6 months from treatment | 9/12 | 5·33 (1·14–24·90) | 7/7 | — | ||
Ab, antibody; BTKi, Bruton tyrosine kinase inhibitors; CAR‐T, chimeric antigen receptor T‐cell; CD, cluster of differentiation; CI, confidence interval; OR, odds ratio; S, Spike protein.
*
OR not estimable, Fisher’s exact test used (P = 0·017) for on treatment/within 6 months versus >6 months.